Novartis and the University of Pennsylvania have issued a clinical update of their cell therapy for paediatric patients with acute lymphoblastic leukaemia (ALL) showing that 36 out of 39 patients, or 92% of trial participants, experienced a complete remission of their disease.
The Food and Drug Administration has given its first approval to a single-agent immunotherapy for cancer – Amgen Inc’s Blincyto (blinatumomab) for the treatment of refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
A kinase inhibitor which is already authorised for myelofibrosis has now been approved by the Food and Drug Administration for polycythemia vera, another bone marrow disorder. The drug, Jakafi (ruxolitinib), was developed by Incyte Pharmaceuticals Inc and Novartis.
GlaxoSmithKline Plc has dropped plans to divest a portfolio of off-patent drugs that do not represent its core business apparently because offers from the potential buyers were below expectations. The company announced the change of strategy on 4 December.
A medical device which is intended to treat congenital malformations of the heart using a regenerative medicine approach has been backed by a syndicate of leading European investors in a €27 million Series B financing round.
Switzerland-based Anergis SA has raised CHF 14.5 million (€12.1 million) from European and US-based investors in order to progress its lead vaccine against birch pollen allergy into a Phase 3 study. The vaccine consists of synthetic long peptides.
Evgen Pharma Plc, which is developing cancer and neurology products based on a naturally occurring chemical, has announced its intention to make an initial public offering of up to £20 million worth of its shares on the AIM market of the London Stock Exchange in mid-December.
BTG Plc is to pay up to $475 million to acquire privately-held PneumRx Inc of California which has a medical device approved in Europe to treat emphysema. The purchase price consists of an upfront payment of $230 million and up to $245 million in milestones.
France-based TxCell SA has enrolled the first patient in a new trial of its cell therapy for Crohn’s disease which aims to demonstrate that 160 patients with refractory disease can experience relief. Crohn’s is an inflammatory bowel disease affecting the gastrointestinal tract.
Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.